• LAST PRICE
    15.9900
  • TODAY'S CHANGE (%)
    Trending Up0.5400 (3.4951%)
  • Bid / Lots
    15.0200/ 1
  • Ask / Lots
    25.5600/ 2
  • Open / Previous Close
    15.5400 / 15.4500
  • Day Range
    Low 15.2500
    High 16.0600
  • 52 Week Range
    Low 10.3800
    High 21.1400
  • Volume
    1,391,162
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 15.45
TimeVolumeTYRA
09:32 ET72215.54
09:38 ET10015.4
09:50 ET70015.33
09:52 ET10015.325
09:54 ET10015.315
09:56 ET10015.315
09:57 ET10015.315
09:59 ET10015.33
10:08 ET76715.415
10:15 ET20515.535
10:17 ET10015.535
10:19 ET30015.535
10:21 ET20015.57
10:24 ET10015.49
10:28 ET10015.42
10:30 ET10015.55
10:32 ET20015.49
10:33 ET20015.5
10:35 ET30015.48
10:39 ET20015.42
10:42 ET20015.49
10:44 ET10015.55
10:48 ET20015.535
10:50 ET10015.525
10:55 ET40015.45
10:57 ET10015.45
11:00 ET20015.5
11:02 ET30015.5
11:04 ET10015.49
11:06 ET10015.48
11:08 ET20015.45
11:09 ET20015.46
11:11 ET60015.4
11:18 ET10015.35
11:22 ET635115.345
11:24 ET5640015.395
11:26 ET210015.31
11:27 ET30015.45
11:29 ET20015.55
11:31 ET30015.63
11:33 ET10015.585
11:36 ET10015.585
11:38 ET20015.61
11:40 ET10015.61
11:42 ET40615.53
11:45 ET20015.465
11:49 ET10015.455
11:51 ET10015.47
11:54 ET20015.52
11:56 ET10015.52
12:05 ET10015.5
12:07 ET30015.66
12:09 ET10015.68
12:12 ET10015.7
12:20 ET30015.71
12:27 ET20015.75
12:30 ET30015.74
12:34 ET21415.84
12:38 ET70015.75
12:41 ET10015.735
12:45 ET10015.7425
12:50 ET41715.64
12:52 ET10015.685
12:54 ET10015.6
12:59 ET10015.6
01:01 ET10015.635
01:03 ET25415.61
01:06 ET10015.6
01:10 ET101815.61
01:12 ET10015.55
01:14 ET31615.56
01:17 ET10015.635
01:19 ET20015.61
01:21 ET61915.585
01:26 ET20015.45
01:30 ET10015.43
01:32 ET10015.42
01:33 ET10015.435
01:35 ET10015.32
01:37 ET20015.34
01:39 ET40015.32
01:48 ET20015.32
01:50 ET50015.28
01:51 ET101815.3
01:53 ET410015.265
01:55 ET127615.31
01:57 ET10015.365
02:00 ET128215.37
02:02 ET20015.51
02:04 ET10015.495
02:08 ET10015.555
02:09 ET56115.5
02:11 ET50015.5
02:24 ET20015.62
02:26 ET10015.6075
02:27 ET40015.6
02:29 ET88815.55
02:31 ET10015.54
02:33 ET10015.58
02:40 ET70015.6
02:42 ET20015.61
02:45 ET40015.6
02:47 ET40015.6
02:49 ET20015.6
02:54 ET10015.6
02:58 ET50015.6
03:00 ET50015.6
03:02 ET40015.6
03:03 ET30015.6
03:05 ET60015.65
03:07 ET10015.65
03:09 ET50015.65
03:12 ET40015.645
03:14 ET10015.59
03:16 ET10015.63
03:20 ET20015.65
03:21 ET10015.7
03:25 ET30415.74
03:27 ET70015.775
03:32 ET75015.735
03:34 ET20015.72
03:36 ET53415.785
03:38 ET10015.76
03:39 ET20015.78
03:41 ET10015.785
03:43 ET62215.8
03:45 ET150015.7
03:48 ET190715.7025
03:50 ET100015.63
03:52 ET562015.8
03:54 ET634915.92
03:56 ET290616
03:57 ET70016.01
03:59 ET76397215.99
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTYRA
Tyra Biosciences Inc
840.1M
-9.5x
---
United StatesRAPP
Rapport Therapeutics Inc
850.8M
-16.0x
---
United StatesVRDN
Viridian Therapeutics Inc
830.3M
-2.9x
---
United StatesSPRY
ARS Pharmaceuticals Inc
824.6M
-16.4x
---
United StatesCOGT
Cogent Biosciences Inc
806.0M
-3.4x
---
United StatesETNB
89Bio Inc
788.1M
-4.0x
---
As of 2024-06-30

Company Information

Tyra Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. Its initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. Its lead product candidate, TYRA-300, is an investigational, oral, FGFR3-selective inhibitor being evaluated in an international, multi-center, open label Phase 1 clinical study, SURF301. Its second oncology product candidate, TYRA-200, is an investigational, oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations, and clinically important molecular brake and gatekeeper resistance mutations.

Contact Information

Headquarters
2656 State StreetCARLSBAD, CA, United States 92008
Phone
619-728-4760
Fax
302-655-5049

Executives

Non-Executive Chairman of the Board
Robert More
President, Chief Executive Officer, Treasurer, Director
Todd Harris
Chief Financial Officer
Alan Fuhrman
Chief Operating Officer
Daniel Bensen
Chief Medical Officer
Hiroomi Tada

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$840.1M
Revenue (TTM)
$0.00
Shares Outstanding
52.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.68
Book Value
$4.75
P/E Ratio
-9.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.